Eli Lilly (LLY) Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why

Eli Lilly and Co. LLY +0.63% ▲ is turning to South Korea for its next big investment.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

The U.S. pharmaceutical giant has agreed to invest $500 million in South Korea over the next five years, one of the largest recent commitments by a global drug maker to the country’s emerging biotechnology industry.

Eli Lilly’s latest move is expected to signal that global big pharma companies are restructuring their Asia research and development operations around Korea. The arrival of an R&D platform from a big pharma company that leads global standards is anticipated to serve as a critical catalyst for Korea’s innovation ecosystem to leap forward.

According to the Ministry of Health and Welfare on the 9th, Lilly Gateway Labs, which Lilly will establish in Korea through this investment, is a shared innovation platform operating in six locations worldwide. Korea is expected to become the second site in Asia after China and the seventh globally.

Experts analyzed that global pharmaceutical companies, which had previously prioritized Singapore and Japan when establishing Asian bases, chose Korea as their top partner due to their high assessment of the qualitative growth of Korea’s clinical pipeline. Currently, Korea’s clinical pipeline ranks third in the world, following the United States and China.

The core of this investment is transplanting Lilly’s global open innovation model to Korea. Gateway Labs, already operating in major bio clusters including San Francisco and Boston in the U.S., goes beyond providing simple laboratory space to promising bio companies. It is a “comprehensive incubating” approach that shares Lilly’s R&D expertise and supports the entire process from preclinical to integrated clinical stages. The platform to be established in Korea is expected to adopt this systematic technical support model and become a key base for Korean companies to grow into global pipelines.

Behind this strategic move lies the unique platform technologies of Korean bio companies. Original technologies recognized as global standards—including Alteogen’s Hybrozyme, LegoChem Biosciences’ ConjuAll, and ABL Bio’s Grabody-B—have proven the status of Korea’s bio industry and have become the decisive factor for big pharma companies to select Korea as a key Asian base, according to analysis.

Lilly is expected to pursue aggressive collaboration with Korean companies across core R&D areas rather than limiting itself to specific fields. Obesity and diabetes (GLP-1), neurological diseases such as Alzheimer’s, and immuno-oncology are expected to be key targets. While collaboration possibilities with companies possessing long-acting injectable technologies such as Peptron and Inventage Lab are being discussed, additional technology convergence models with ABL Bio, which already has a partnership, are also expected in the neurological disease field.

Particularly noteworthy is Lilly’s artificial intelligence drug development strategy. Lilly has made rapid candidate compound discovery using AI a top priority by establishing an AI innovation lab jointly with AI semiconductor company Nvidia and operating its own machine learning platform “Lilly TuneLab.” As Lilly is advancing its vast accumulated clinical data through AI models, Korean AI drug development companies with technological capabilities are highly likely to move into Gateway Labs and utilize Lilly’s infrastructure. If Korean companies combine with such platforms, they are expected to gain opportunities to dramatically shorten the drug candidate discovery period.

Patrick Johnson, President of Lilly International, emphasized, “We hope this agreement will help Korea grow as a global leader in the pharmaceutical and bio industry and contribute to patient treatment and public health improvement, including better access to innovative medicines.”

Global big pharma’s move to Korea is spreading across the industry, not just Eli Lilly. Roche recently confirmed a large-scale investment of approximately 710 billion won in Korea and has embarked on building a data-driven precision medicine ecosystem. AstraZeneca is also working closely with Korean researchers and focusing its capabilities on discovering next-generation innovative technologies. Selecting Korea as a core partner for drug development beyond simple market acquisition is interpreted as a result of highly valuing the technological potential of Korean bio companies and their world-class clinical infrastructure. This series of investments is analyzed as demonstrating that Korea has firmly established itself as a unique innovation base representing Asia within the global pharmaceutical and bio supply chain. An official from a Korean pharmaceutical and bio industry company said, “If the ‘co-growth model’ proven in major countries such as the UK successfully takes root in Korea, it will become a catalyst for improving the structure of the domestic industry,” adding, “Korea is establishing itself as an essential base leading big pharma’s Asian innovation and as a hub for drug development, going beyond simple contract manufacturing.”

Disclaimer & DisclosureReport an Issue